Drugs / HER2-specific chimeric antigen receptor (CAR) T cell
HER2-specific chimeric antigen receptor (CAR) T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03500991 | Jul 2018 → Jan 2024 overdue | atypical teratoid rhabdoid tumor, choroid plexus carcinoma, ependymoma, germ cell tumor +3 | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2-specific chimeric antigen receptor (CAR) T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03500991 ↗ |
| Modality | Cell therapy | “Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt” NCT03500991 ↗ |
| Route | Other | “will then be administered via the indwelling CNS catheter” NCT03500991 ↗ |